{"title":"THE EFFECT OF ORAL VITAMIN D ON TUMOR NECROSIS FACTOR-? EXPRESSION IN TRABECULAR MESHWORK OF WISTAR GLAUCOMA MODEL","authors":"Rikha Erina, Andrini Ariesti, Hendriati","doi":"10.35749/vrszrr85","DOIUrl":null,"url":null,"abstract":"Introduction & ObjectivesElevated intraocular pressure (IOP) is a risk factor for the development and progression of glaucomathat can induces inflammation in the trabecular meshwork through the production of proinflammatorycytokines such as TNF-?. Inflammation induce mechanical stress and changes in theextracellular matrix in the trabecular meshwork, resulting in hypertonicity and resistance toaqueous humor outflow. Vitamin D can modulate cytokine production by suppressing TH1 cellexpression and inducing TH2 cell expression. The production of pro-inflammatory cytokines can besuppressed by the presence of vitamin D. \nMethodsAn experimental study of 30 wistar glaucoma model were divided into 3 groups, non treatmentgroup ( A and B) and the oral vitamin D (1200 IU/kg/day) group (C) for 14 days. TNF-? expressionsin trabecular meshwork were measured by immunohistochemical staining. Group A was measuredon day 3, while group B and C were measured on day 14. The differences between the three groupswere analyzed statistically using one way ANOVA test. Significantly different if the p<0.05. \nResultsThe mean expression of TNF- ? in the trabecular meshwork of wistar glaucoma model in group A, B,and C was 22,2 ± 2,51%, 39,1 ± 3.98%, 34.2 ± 3,19 % respectively. There was significantlydifference in TNF-? expressions between the three groups (p<0.001). \nConclusionVitamin D per oral can decrease TNF-? expression in the trabecular meshwork of wistar glaucomamodel on day 14 . Studies in wistar and humans are still needed to assess the effect of vitamin D onothers pro-inflammatory cytokines in glaucoma.","PeriodicalId":165753,"journal":{"name":"Ophthalmologica Indonesiana","volume":"35 19","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmologica Indonesiana","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35749/vrszrr85","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction & ObjectivesElevated intraocular pressure (IOP) is a risk factor for the development and progression of glaucomathat can induces inflammation in the trabecular meshwork through the production of proinflammatorycytokines such as TNF-?. Inflammation induce mechanical stress and changes in theextracellular matrix in the trabecular meshwork, resulting in hypertonicity and resistance toaqueous humor outflow. Vitamin D can modulate cytokine production by suppressing TH1 cellexpression and inducing TH2 cell expression. The production of pro-inflammatory cytokines can besuppressed by the presence of vitamin D.
MethodsAn experimental study of 30 wistar glaucoma model were divided into 3 groups, non treatmentgroup ( A and B) and the oral vitamin D (1200 IU/kg/day) group (C) for 14 days. TNF-? expressionsin trabecular meshwork were measured by immunohistochemical staining. Group A was measuredon day 3, while group B and C were measured on day 14. The differences between the three groupswere analyzed statistically using one way ANOVA test. Significantly different if the p<0.05.
ResultsThe mean expression of TNF- ? in the trabecular meshwork of wistar glaucoma model in group A, B,and C was 22,2 ± 2,51%, 39,1 ± 3.98%, 34.2 ± 3,19 % respectively. There was significantlydifference in TNF-? expressions between the three groups (p<0.001).
ConclusionVitamin D per oral can decrease TNF-? expression in the trabecular meshwork of wistar glaucomamodel on day 14 . Studies in wistar and humans are still needed to assess the effect of vitamin D onothers pro-inflammatory cytokines in glaucoma.